Traws Pharma, Inc. filed a Form 8-K on November 12, 2026, disclosing Phase 2a results for Ratutrelvir and the completion of a bridging study of Tivoxavir Marboxil via a press release furnished under Regulation FD.

Key Highlights

  • Phase 2a results announced: Traws Pharma disclosed Phase 2a results for Ratutrelvir, described in the filing as "an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus, the causative agent in COVID-19."
  • Bridging study completed: According to the filing, the company also announced the completion of a bridging study of Tivoxavir Marboxil.
  • Disclosure method: The clinical announcements were made through a press release dated November 12, 2026, attached as Exhibit 99.1.
  • Furnished, not filed: The filing states the information "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934."
  • Signed by CFO: The report was signed by Charles Parker, Chief Financial Officer of Traws Pharma, Inc.

Traws Pharma Discloses Ratutrelvir Phase 2a Data and Tivoxavir Bridging Study Completion

Traws Pharma, Inc. (NASDAQ:TRAW) filed a current report on November 12, 2026, under Item 7.01 (Regulation FD Disclosure), announcing two clinical development updates. The company disclosed Phase 2a results for Ratutrelvir, which the filing identifies as an inhibitor of the main protease, also referred to as the 3CL protease, of the SARS-CoV-2 virus. The filing does not include the detailed numerical results of the Phase 2a study within the 8-K body itself; those results are contained in the attached press release, Exhibit 99.1.

In addition to the Ratutrelvir data, the filing states that Traws Pharma announced the completion of a bridging study of Tivoxavir Marboxil. No further details about the bridging study's scope or findings are included in the 8-K body text. The press release, dated November 12, 2026, is incorporated by reference into Item 7.01 of the current report.

The filing notes that the information furnished under Item 7.01, including Exhibit 99.1, is not deemed "filed" for Section 18 liability purposes and is not automatically incorporated by reference into other company filings under the Exchange Act or the Securities Act of 1933. The company also cautions that the current report contains forward-looking statements that "involve substantial risks and uncertainties," and that actual results could differ from those expressed or implied by such statements. The report was signed by Charles Parker in his capacity as Chief Financial Officer.

What Was Disclosed

Traws Pharma furnished a Regulation FD current report on November 12, 2026, announcing Phase 2a results for the COVID-19 antiviral Ratutrelvir and completion of a bridging study for Tivoxavir Marboxil, with detailed findings provided in the attached press release.